<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b4da2728-c603-4330-9abe-88d375e67f40"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AFREZZA<sup>®</sup> safely and effectively. See full prescribing information for AFREZZA.<br/>
      <br/>AFREZZA<sup>®</sup> (insulin human) inhalation powder, for oral inhalation use<br/>Initial U.S. Approval: 2014
</title>
   <effectiveTime value="20230227"/>
   <setId root="29f4637b-e204-425b-b89c-7238008d8c10"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="099981040" root="1.3.6.1.4.1.519.1"/>
            <name>Mannkind Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="099981040" root="1.3.6.1.4.1.519.1"/>
                        <name>Mannkind Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-874" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-874" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-874" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-874" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-878" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-878" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-878" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-878" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-891" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-891" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-891" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-891" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-880" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-880" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-880" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-880" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-898" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-898" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-898" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-898" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-902" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-902" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-902" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-902" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-903" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-903" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-903" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47918-903" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="87fb2d93-db8c-4556-a4b4-f4f5624542b0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20230227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-874" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="4" unit="[arb'U]"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INSULIN HUMAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARYL DIKETOPIPERAZINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="15" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="2" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="3" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code code="47918-874-90" codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                             </containerPackagedProduct>
                                             <subjectOf>
                                                <marketingAct>
                                                   <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                                   <statusCode code="active"/>
                                                   <effectiveTime>
                                                      <low value="20150121"/>
                                                   </effectiveTime>
                                                </marketingAct>
                                             </subjectOf>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150121"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-878" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="8" unit="[arb'U]"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INSULIN HUMAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARYL DIKETOPIPERAZINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="15" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="2" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="3" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code code="47918-878-90" codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                             </containerPackagedProduct>
                                             <subjectOf>
                                                <marketingAct>
                                                   <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                                   <statusCode code="active"/>
                                                   <effectiveTime>
                                                      <low value="20170701"/>
                                                   </effectiveTime>
                                                </marketingAct>
                                             </subjectOf>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170701"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-891" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="12" unit="[arb'U]"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INSULIN HUMAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARYL DIKETOPIPERAZINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="15" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="2" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="3" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code code="47918-891-90" codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                             </containerPackagedProduct>
                                             <subjectOf>
                                                <marketingAct>
                                                   <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                                   <statusCode code="active"/>
                                                   <effectiveTime>
                                                      <low value="20170701"/>
                                                   </effectiveTime>
                                                </marketingAct>
                                             </subjectOf>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170701"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-880" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="47918-880-18" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160701"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="8" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="3" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="4" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="3" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160701"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-898" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="47918-898-18" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181204"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="8" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="3" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="12" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="3" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181204"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-902" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="47918-902-18" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170110"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="8" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="2" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="4" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="2" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="12" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="15" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                          <asContent>
                                             <quantity>
                                                <numerator value="2" unit="1"/>
                                                <denominator value="1" unit="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                                <asContent>
                                                   <quantity>
                                                      <numerator value="2" unit="1"/>
                                                      <denominator value="1" unit="1"/>
                                                   </quantity>
                                                   <containerPackagedProduct>
                                                      <code codeSystem="2.16.840.1.113883.6.69"/>
                                                      <formCode code="C43198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE, COMBINATION"/>
                                                   </containerPackagedProduct>
                                                </asContent>
                                             </containerPackagedProduct>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47918-903" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AFREZZA</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INSULIN HUMAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="47918-903-27" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="9" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="8" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="9" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="9" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="4" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="9" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="9" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>AFREZZA</name>
                              <formCode code="C42961" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, METERED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>INSULIN HUMAN</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="12" unit="[arb'U]"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INSULIN HUMAN</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XB09609XSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARYL DIKETOPIPERAZINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTRIDGE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="9" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140711"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA022472" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="51a639cb-cbf7-485e-98d3-3fe8496c6b78"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE
</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and COPD 
</content>
                        <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s14">5.1</linkHtml>)]</content>
                        <content styleCode="bold">.</content>
                     </item>
                     <item>
                        <content styleCode="bold">AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD
</content>
                        <content styleCode="bold italics">[see Contraindications (<linkHtml href="#s12">4</linkHtml>)].</content>
                     </item>
                     <item>
                        <content styleCode="bold">Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV</content>
                        <content styleCode="bold">
                           <sub>1</sub>
                        </content>
                        <content styleCode="bold">) to identify potential lung disease in all patients
</content>
                        <content styleCode="bold italics">[see Dosage and Administration (<linkHtml href="#s9">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#s14">5.1</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and COPD. (<linkHtml href="#s14">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. (<linkHtml href="#s12">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV</content>
                              <content styleCode="bold">
                                 <sub>1</sub>
                              </content>
                              <content styleCode="bold">) to identify potential lung disease in all patients. (<linkHtml href="#s9">2.5</linkHtml>), (<linkHtml href="#s14">5.1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="f891640b-8b6c-4ad5-b54a-b6aa12d6d961"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>AFREZZA<sup>®</sup> is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>AFREZZA is not recommended for the treatment of diabetic ketoacidosis <content styleCode="italics">[see Warning and Precautions (<linkHtml href="#s20">5.6</linkHtml>)]</content>.
</item>
                     <item>The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.
</item>
                  </list>
               </text>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>AFREZZA<sup>®</sup> is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. (<linkHtml href="#s3">1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Not recommended for the treatment of diabetic ketoacidosis (<linkHtml href="#s3">1</linkHtml>)
</item>
                           <item>Not recommended in patients who smoke or who have recently stopped smoking (<linkHtml href="#s3">1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="0f9cd512-897b-43ba-ab38-8348d10486cf"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Only administer via oral inhalation using the AFREZZA inhaler (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                           <item>Administer at the beginning of each meal (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                           <item>See full prescribing information for the recommended starting mealtime dosage in insulin-naïve patients and patients who are using subcutaneous mealtime insulin or pre-mixed insulin (<linkHtml href="#s7">2.3</linkHtml>)
</item>
                           <item>Modify dosage based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal (<linkHtml href="#s7">2.3</linkHtml>)
</item>
                           <item>If blood glucose control is not achieved in patients requiring high AFREZZA doses, consider discontinuing AFREZZA (<linkHtml href="#s8">2.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5">
                     <id root="fec672da-9503-44e2-8fc8-17d4de55b21f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1   Lung Function Assessment Prior to Administration
</title>
                     <text>
                        <paragraph>AFREZZA is contraindicated in patients with chronic lung disease because of the risk of acute bronchospasm in these patients. Before initiating AFREZZA, perform a medical history, physical examination and spirometry (FEV<sub>1</sub>) in all patients to identify potential lung disease <content styleCode="italics">[see Contraindications (<linkHtml href="#s12">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s14">5.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="fbb2b6a4-6341-4994-9d50-530c9aca7380"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2   Important Administration and Discard Instructions
</title>
                     <text>
                        <paragraph>Only administer AFREZZA via oral inhalation using the AFREZZA Inhaler. Administer AFREZZA at the beginning of each meal. Administer AFREZZA using a single inhalation per cartridge (if the dose is greater than the contents of a single cartridge, more than one cartridge is needed) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s7">2.3</linkHtml>)].</content> For additional administration instructions on how to use the AFREZZA Inhaler <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.6</linkHtml>)]</content> and see the <content styleCode="italics">
                              <linkHtml href="#s88">Instructions for Use</linkHtml>.</content>
                        </paragraph>
                        <paragraph>The AFREZZA Inhaler can be used for up to 15 days from the date of first use. After 15 days of use, the inhaler must be discarded and replaced with a new inhaler.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="ecdace24-12e5-4ed5-a334-73862ec13225"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3   Recommended Starting Mealtime Dosage
</title>
                     <text>
                        <paragraph>For insulin naïve patients, start on 4 units of AFREZZA at the beginning of each meal.
</paragraph>
                        <paragraph>For patients using subcutaneous, <content styleCode="underline">mealtime</content> (<content styleCode="italics">prandial) insulin:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Determine the appropriate AFREZZA dose for each meal by converting from the injected insulin dose using <linkHtml href="#fig1">Figure 1</linkHtml>.
</item>
                           <item>When switching from another insulin to AFREZZA, a different insulin dose may be needed requiring increased frequency of blood glucose monitoring <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.2</linkHtml>)].</content>
                           </item>
                        </list>
                        <paragraph>For patients using subcutaneous, <content styleCode="underline">pre-mixed insulin</content>:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Estimate the mealtime injected dose by dividing half of the total daily injected pre-mixed insulin dose equally among the three meals of the day. When switching from another insulin to AFREZZA, a different insulin dose may be needed. When switching a patient's insulin regimen, increase the frequency of blood glucose monitoring <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.2</linkHtml>)].</content>
                           </item>
                           <item>Convert each estimated injected mealtime dose to an appropriate AFREZZA dose using <linkHtml href="#fig1">Figure 1</linkHtml>.
</item>
                           <item>Administer half of the total daily injected pre-mixed dose as an injected basal insulin dose.
</item>
                        </list>
                        <paragraph>For AFREZZA doses exceeding the contents of a single cartridge at mealtime, inhalations from more than one cartridge are necessary. To achieve the required total mealtime dose, use a combination of 4 unit, 8 unit, and 12 unit cartridges. Examples of cartridge combinations for doses of up to 24 units are shown in <linkHtml href="#fig1">Figure 1</linkHtml>. For doses above 24 units, use combinations of different multiple cartridges.
</paragraph>
                        <paragraph ID="fig1">
                           <content styleCode="bold">Figure 1. Mealtime AFREZZA Starting Dose Conversion Table</content>
                        </paragraph>
                        <renderMultiMedia ID="f01" referencedObject="mm01"/>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <observationMedia ID="mm01">
                           <text>Figure 1
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="afr01-0005-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="7380f6af-1e14-4d34-80e8-f574f0a71491"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4   Mealtime Dosage Modification
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Modify the AFREZZA dosage based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal.
</item>
                           <item>Dosage modifications may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#s49">8.6</linkHtml>, <linkHtml href="#s50">8.7</linkHtml>)].</content>
                           </item>
                           <item>Carefully monitor blood glucose control in patients requiring high AFREZZA doses. If blood glucose control is not achieved with increased AFREZZA doses in these patients, consider discontinuing AFREZZA.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="701c2c4d-0e64-4ed9-a17a-1e47e1f38f8e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5   Dosage Modifications for Drug Interactions
</title>
                     <text>
                        <paragraph>Dosage modification may be needed when:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>AFREZZA is used concomitantly with certain drugs that increase and/or decrease the glucose lowering effect <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s32">7.1</linkHtml>, <linkHtml href="#s33">7.2</linkHtml>, <linkHtml href="#s34">7.3</linkHtml>)].</content>
                           </item>
                           <item>Switching from another insulin to AFREZZA <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.2</linkHtml>) and Warnings and Precautions (<linkHtml href="#s15">5.2</linkHtml>)]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="8f2d1c2b-c30e-4729-83be-1fa6bab8d084"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6   Administration Instructions
</title>
                     <text>
                        <paragraph>Refer patients to the <content styleCode="italics">
                              <linkHtml href="#s88">Instructions for Use</linkHtml>
                           </content> for detailed instructions and visuals on how to prepare, administer, and store AFREZZA; use the AFREZZA cartridges; and use the AFREZZA inhaler. Critical administration instructions are as follows:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Keep the inhaler level with the white mouthpiece on top and purple base on the bottom after a cartridge has been inserted into the inhaler. Loss of drug effect can occur if the inhaler is turned upside down, held with the mouthpiece pointing down, shaken, or dropped after the cartridge has been inserted but before the dose has been administered. If any of the above occur, replace the cartridge before use.
</item>
                           <item>Hold the inhaler away from the mouth and fully exhale.
</item>
                           <item>After the inhaler is placed in the mouth and the lips form a seal, tilt the inhaler down towards the chin while keeping the head level.
</item>
                           <item>With the mouth closed around the mouthpiece, inhale deeply through the inhaler.
</item>
                           <item>Hold the breath for as long as comfortable and at the same time remove the inhaler from the mouth.
</item>
                           <item>After holding the breath, exhale and continue to breathe normally.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="42e5d48e-4dfe-48d3-a712-7a2027167896"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Inhalation Powder: single-use cartridges containing 4 units, 8 units or 12 units of insulin human as white powder to be administered via oral inhalation with the AFREZZA inhaler only <content styleCode="italics">[see How Supplied/Storage and Handling (<linkHtml href="#s74">16</linkHtml>)]</content>.
</paragraph>
               </text>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Inhalation powder in single-use cartridges of: 4 units, 8 units, or 12 units (<linkHtml href="#s11">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="5ec7ec34-188d-44b1-bbae-2a0b719024ea"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>AFREZZA is contraindicated:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>During episodes of hypoglycemia <content styleCode="italics">[see Warning and Precautions (<linkHtml href="#s16">5.3</linkHtml>)].</content>
                     </item>
                     <item>Chronic lung disease, such as asthma or chronic obstructive pulmonary disease (COPD), because of the risk of acute bronchospasm <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity to regular human insulin or any of the excipients in AFREZZA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>During episodes of hypoglycemia (<linkHtml href="#s12">4</linkHtml>)
</item>
                           <item>Chronic lung disease, such as asthma, or chronic obstructive pulmonary disease (<linkHtml href="#s12">4</linkHtml>)
</item>
                           <item>Hypersensitivity to regular human insulin or any of the excipients in AFREZZA (<linkHtml href="#s12">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="43719e9c-9ad9-4aab-a71d-b41c1063b31f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  Warnings and Precautions
</title>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen</content>: Carry out under close medical supervision and increase frequency of blood glucose monitoring. For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed. (<linkHtml href="#s15">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia</content> (may be life-threatening): Increase frequency of glucose monitoring in patients at higher risk for hypoglycemia and those who have reduced symptomatic awareness of hypoglycemia. (<linkHtml href="#s16">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Decline in Pulmonary Function</content>: Assess pulmonary function (e.g., spirometry (FEV<sub>1</sub>)) before initiating, after 6 months of therapy, and annually, even in the absence of pulmonary symptoms. In patients who have a decline of ≥ 20% in FEV<sub>1</sub> from baseline, consider discontinuing AFREZZA. (<linkHtml href="#s9">2.5</linkHtml>, <linkHtml href="#s18">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Lung Cancer</content>: In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk. (<linkHtml href="#s19">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Diabetic Ketoacidosis</content>: In patients at risk for DKA, increase the frequency of glucose monitoring and consider changing to alternate route of insulin delivery. (<linkHtml href="#s20">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity Reactions</content>: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA. If hypersensitivity reactions occur, discontinue AFREZZA, treat per standard of care and monitor until symptoms and signs resolve. (<linkHtml href="#s21">5.7</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypokalemia</content> (may be life-threatening): Monitor potassium levels in patients at risk of hypokalemia. (<linkHtml href="#s22">5.8</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs)</content>: Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. (<linkHtml href="#s23">5.9</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s14">
                     <id root="28d8ec3c-3c13-4852-8d1e-8cd0b55dfca1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1   Acute Bronchospasm in Patients with Chronic Lung Disease
</title>
                     <text>
                        <paragraph>Because of the risk of acute bronchospasm, AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD <content styleCode="italics">[see Contraindications (<linkHtml href="#s12">4</linkHtml>)]</content>.  Before initiating therapy with AFREZZA, evaluate all patients with a medical history, physical examination, and spirometry (FEV<sub>1</sub>) to identify potential underlying lung disease.
</paragraph>
                        <paragraph>Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and COPD. In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5 out of 17) and 0% (0 out of 13) of patients with and without a diagnosis of asthma, respectively. In this study, a mean decline in FEV<sub>1</sub> of 400 mL was observed 15 minutes after a single AFREZZA dose in patients with asthma. In a subset study of patients with COPD (n=8), a mean decline in FEV<sub>1</sub> of 200 mL was observed 18 minutes after a single AFREZZA dose.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="4c68fae3-620c-4320-8b74-8cd67108dec4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2   Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen
</title>
                     <text>
                        <paragraph>Glucose monitoring is essential for patients receiving insulin therapy. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)]</content> or hyperglycemia. These changes should be made under close medical supervision and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage modifications of concomitant oral antidiabetic treatment may be needed <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s32">7.1</linkHtml>, <linkHtml href="#s33">7.2</linkHtml>, and <linkHtml href="#s34">7.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="05d0eb7c-37e6-464e-8a98-6a5d805903fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3   Hypoglycemia
</title>
                     <text>
                        <paragraph>Glucose monitoring is essential for patients receiving insulin therapy. Hypoglycemia is the most common adverse reaction associated with insulins, including AFREZZA. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).
</paragraph>
                        <paragraph>The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. AFREZZA has a distinct time action profile <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s55">12</linkHtml>)]</content>, which impacts the timing of hypoglycemia. Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using certain medications <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s35">7.4</linkHtml>)]</content>, or in patients who experience recurrent hypoglycemia.
</paragraph>
                        <paragraph>Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s31">7</linkHtml>)]</content>. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s49">8.6</linkHtml>, <linkHtml href="#s50">8.7</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s17">
                           <id root="6ee0a1ba-4837-4a8d-9a0d-95492ccf2477"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Mitigation Strategies for Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Patients and caregivers should be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="5ac974e3-fdb0-43c3-971d-7cd4adb3d955"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4   Decline in Pulmonary Function
</title>
                     <text>
                        <paragraph>AFREZZA causes a decline in pulmonary function over time as measured by FEV<sub>1</sub>. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, AFREZZA-treated patients experienced a small [40 mL (95% CI: -80, -1)] but greater FEV<sub>1</sub> decline than comparator-treated patients. The FEV<sub>1</sub> decline was noted within the first 3 months, and persisted for the entire duration of therapy (up to 2 years of observation). In this population, the annual rate of FEV<sub>1</sub> decline did not appear to worsen with increased duration of use. The effects of AFREZZA on pulmonary function for treatment duration longer than 2 years has not been established. There are insufficient data in long term studies to draw conclusions regarding reversal of the effect on FEV<sub>1</sub> after discontinuation of AFREZZA. The observed changes in FEV<sub>1</sub> were similar in patients with type 1 and type 2 diabetes.
</paragraph>
                        <paragraph>Assess pulmonary function (e.g., spirometry) at baseline, after the first 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms. In patients who have a decline of ≥ 20% in FEV<sub>1</sub> from baseline, consider discontinuing AFREZZA. Consider more frequent monitoring of pulmonary function in patients with pulmonary symptoms such as wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s24">6</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="b572af38-eac8-4a64-a8a8-e9b1608cea36"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5   Lung Cancer
</title>
                     <text>
                        <paragraph>In clinical trials, two cases of lung cancer, one in controlled trials and one in uncontrolled trials (2 cases in 2,750 patient-years of exposure), were observed in patients exposed to AFREZZA while no cases of lung cancer were observed in patients exposed to comparators (0 cases in 2,169 patient-years of exposure). In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) occurred in non-smokers exposed to AFREZZA and were reported by investigators after clinical trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors.
</paragraph>
                        <paragraph>In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="214132ad-ac68-4627-a9f1-759e52c6e07d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6   Diabetic Ketoacidosis
</title>
                     <text>
                        <paragraph>In clinical trials enrolling patients with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in AFREZZA-treated patients (0.43%; n=13) than in comparator-treated patients (0.14%; n=3). Patients with type 1 diabetes should always use AFREZZA in combination with basal insulin. In patients at risk for DKA, such as those with an acute illness or infection, increase the frequency of glucose monitoring and consider discontinuing AFREZZA and giving insulin using an alternate route of administration.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="08150607-76db-4174-8a7f-db2d3349db06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7   Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA.
</paragraph>
                        <paragraph>If hypersensitivity reactions occur, discontinue AFREZZA, treat per standard of care and monitor until symptoms and signs resolve <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s24">6</linkHtml>)]</content>. AFREZZA is contraindicated in patients who have had hypersensitivity reactions to AFREZZA or any of its excipients <content styleCode="italics">[see Contraindications (<linkHtml href="#s12">4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="9e097571-c810-4c99-a194-c6a09750de23"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8   Hypokalemia
</title>
                     <text>
                        <paragraph>All insulin products, including AFREZZA, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death.
</paragraph>
                        <paragraph>Monitor potassium levels in AFREZZA-treated patients at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations and patients receiving intravenously administered insulin).
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="a06a4ce6-2fec-4003-a699-ba95d996c169"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9   Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
</title>
                     <text>
                        <paragraph>Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure.
</paragraph>
                        <paragraph>Patients treated with insulin, including AFREZZA, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist should be considered.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="3b4c2c2e-9351-4600-83c1-ded50e238d41"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below and elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Acute bronchospasm in patients with chronic lung disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)]</content>
                     </item>
                     <item>Decline in pulmonary function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.4</linkHtml>)]</content>
                     </item>
                     <item>Lung cancer <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.5</linkHtml>)]</content>
                     </item>
                     <item>Diabetic ketoacidosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.6</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions associated with AFREZZA (2% or greater incidence) are hypoglycemia, cough, and throat pain or irritation (<linkHtml href="#s24">6</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact MannKind at 1-877-323-8505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s25">
                     <id root="bb9610ab-7aa4-4839-9fe1-626d7edb3624"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1   Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>The data described below reflect exposure of 3,017 patients to AFREZZA and include 1,026 patients with type 1 diabetes and 1,991 patients with type 2 diabetes. The mean exposure duration was 8.2 months for patients with type 1 diabetes and those with type 2 diabetes. In the overall population:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>1,874 patients were exposed to AFREZZA for 6 months and 724 patients for greater than one year.
</item>
                           <item>620 and 1,254 patients with type 1 and type 2 diabetes, respectively, were exposed to AFREZZA for up to 6 months.
</item>
                           <item>238 and 486 patients with type 1 and type 2 diabetes, respectively, were exposed to AFREZZA for greater than one year (median exposure = 1.8 years).
</item>
                        </list>
                        <paragraph>AFREZZA was studied in placebo and active-controlled trials (n = 3 and n = 10, respectively).
</paragraph>
                        <paragraph>The mean age of the population was 50.2 years and 20 patients were older than 75 years of age; 51% of the population were males; 83% were White, 5% were Black or African American, and 2% were Asian; 10% were Hispanic. At baseline, the type 1 diabetes population had diabetes for an average of 16.6 years and had a mean HbA1c of 8.3%, and the type 2 diabetes population had diabetes for an average of 10.7 years and had a mean HbA1c of 8.8%. At baseline, 33% of the population reported peripheral neuropathy, 32% reported retinopathy and 20% had a history of cardiovascular disease.
</paragraph>
                        <paragraph>
                           <linkHtml href="#t1">Table 1</linkHtml> shows the frequency of common adverse reactions, excluding hypoglycemia, associated with the use of AFREZZA in the pool of controlled trials in type 2 diabetes patients. These adverse reactions were not present at baseline, occurred more commonly on AFREZZA than on placebo and/or comparator and occurred in at least 2% of patients treated with AFREZZA.
</paragraph>
                        <table ID="t1" width="100%" styleCode="Noautorules">
                           <caption>Table 1. Common Adverse Reactions That Occurred in ≥ 2% in Patients with Type 2 Diabetes Mellitus (excluding Hypoglycemia) Treated with AFREZZA
</caption>
                           <col width="33.500%" align="left"/>
                           <col width="20.350%" align="left"/>
                           <col width="22.225%" align="left"/>
                           <col width="23.925%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top">
                                    <paragraph styleCode="footnote">*Carrier particle without insulin was used as placebo <content styleCode="italics">[see Description (<linkHtml href="#s53">11.1</linkHtml>)]</content>.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">
                                    <content styleCode="bold">AFREZZA</content>
                                    <br/>
                                    <content styleCode="bold">(n = 1,991)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Placebo*</content>
                                    <br/>
                                    <content styleCode="bold">(n = 290)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Non-placebo comparators (n=1,363)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Cough
</td>
                                 <td rowspan="7" align="center" valign="middle" styleCode="Botrule Rrule">25.6%<br/>4.4%<br/>3.1%<br/>2.7%<br/>2.2%<br/>2.0%<br/>2.0%
</td>
                                 <td rowspan="7" align="center" valign="middle" styleCode="Botrule Rrule">19.7%<br/>3.8%<br/>2.8%<br/>1.4%<br/>1.0%<br/>0.7%<br/>0.3%
</td>
                                 <td rowspan="7" align="center" valign="middle" styleCode="Botrule Rrule">5.4%<br/>0.9%<br/>1.8%<br/>2.2%<br/>0.9%<br/>0.6%<br/>1.0%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Throat pain or irritation
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Headache
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Diarrhea
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Productive cough
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Fatigue
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#t2">Table 2</linkHtml> shows the frequency of common adverse reactions, excluding hypoglycemia, associated with the use of AFREZZA in the pool of active-controlled trials in type 1 diabetes patients. These adverse reactions were not present at baseline, occurred more commonly on AFREZZA than on comparator, and occurred in at least 2% of patients treated with AFREZZA.
</paragraph>
                        <table ID="t2" width="100%" styleCode="Noautorules">
                           <caption>Table 2. Common Adverse Reactions That Occurred in ≥ 2% in Patients with Type 1 Diabetes Mellitus (excluding Hypoglycemia) Treated with AFREZZA
</caption>
                           <col width="49.033%" align="left"/>
                           <col width="25.533%" align="left"/>
                           <col width="25.433%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">
                                    <content styleCode="bold">AFREZZA<br/>(n=1026)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Subcutaneous Insulin</content>
                                    <br/>
                                    <content styleCode="bold">(n = 835)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Cough
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">29.4%
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">4.9%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Throat pain or irritation
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">5.5%
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">1.9%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Headache
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">4.7%
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">2.8%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Pulmonary function test decreased
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">2.8%
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">1.0%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">Bronchitis
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">2.5%
</td>
                                 <td align="center" valign="middle" styleCode="Rrule">2.0%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Urinary tract infection
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">2.3%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">1.9%
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s26">
                           <id root="28f74f6e-75e2-4546-ae69-f5c2dc14d5b5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including AFREZZA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)]</content>. The incidence of severe and non-severe hypoglycemia in AFREZZA-treated patients versus placebo-treated patients with type 2 diabetes is shown in <linkHtml href="#t3">Table 3</linkHtml>. A hypoglycemic episode was recorded if a patient reported symptoms of hypoglycemia with or without a blood glucose value consistent with hypoglycemia. Severe hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a blood glucose value consistent with hypoglycemia or prompt recovery after treatment for hypoglycemia.
</paragraph>
                              <table ID="t3" width="100%" styleCode="Noautorules">
                                 <caption>Table 3. Incidence of Severe and Non-Severe Hypoglycemia in a Placebo-Controlled Study of Patients with Type 2 Diabetes
</caption>
                                 <col width="50.833%" align="left"/>
                                 <col width="23.733%" align="left"/>
                                 <col width="25.433%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">AFREZZA</content>
                                          <br/>
                                          <content styleCode="bold">(N=177)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=176)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Severe Hypoglycemia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5.1%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1.7%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-Severe Hypoglycemia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">67%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">30%
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s27">
                           <id root="06576e12-c182-4c61-a0b5-a05b96130ee9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cough</content>
                              </paragraph>
                              <paragraph>Approximately 27% of patients treated with AFREZZA reported cough, compared to approximately 5% of patients treated with comparator. In clinical trials, cough was the most common reason for discontinuation of AFREZZA therapy (3% of AFREZZA-treated patients).
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s28">
                           <id root="423e14e1-3304-438b-9643-e66967010db8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pulmonary Function Decline</content>
                              </paragraph>
                              <paragraph>In clinical trials lasting up to 2 years, excluding patients with chronic lung disease, patients treated with AFREZZA had a 40 mL (95% CI: -80, -1) greater decline from baseline in forced expiratory volume in one second (FEV<sub>1</sub>) compared to patients treated with comparator anti-diabetes treatments. The decline occurred during the first 3 months of therapy and persisted over 2 years (<linkHtml href="#fig2">Figure 2</linkHtml>). A decline in FEV<sub>1</sub> of ≥ 15% occurred in 6% of AFREZZA-treated patients compared to 3% of comparator-treated patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.4</linkHtml>)].</content>
                              </paragraph>
                              <paragraph ID="fig2">
                                 <content styleCode="bold">Figure 2. Mean (+/-SE) Change in FEV</content>
                                 <content styleCode="bold">
                                    <sub>1
</sub>
                                 </content>
                                 <content styleCode="bold">(Liters) from Baseline for Type 1 and Type 2 Diabetes Patients</content>
                              </paragraph>
                              <renderMultiMedia ID="f02" referencedObject="mm02"/>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm02">
                           <text>Figure 2
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="afr01-0005-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <section ID="s29">
                           <id root="c3db1a40-c770-4374-a4c3-3ab5988cabcf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight Gain</content>
                              </paragraph>
                              <paragraph>Weight gain has occurred with some insulin therapies, including AFREZZA. Weight gain has been attributed to the anabolic effects of insulin and the decrease in glycosuria. In a clinical trial of patients with type 2 diabetes <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s72">14.3</linkHtml>)]</content>, there was a mean 0.49 kg weight gain among AFREZZA-treated patients compared with a mean 1.13 kg weight loss among placebo-treated patients.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s30">
                     <id root="f43d19dd-e6fa-4f6e-9c65-88fc8a932469"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2   Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reaction has been identified during post approval use of AFREZZA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: bronchospasm.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s31">
               <id root="61c3496a-dbd3-4918-ab83-5b4bccc4e96e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS
</title>
               <effectiveTime value="20230227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Drugs that may increase the risk of hypoglycemia (<linkHtml href="#s32">7.1</linkHtml>, <linkHtml href="#s34">7.3</linkHtml>)
</item>
                           <item>Drugs that may decrease blood glucose lowering effect of AFREZZA (<linkHtml href="#s33">7.2</linkHtml>, <linkHtml href="#s34">7.3</linkHtml>)
</item>
                           <item>Drugs that may affect hypoglycemic signs and symptoms (<linkHtml href="#s35">7.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s32">
                     <id root="cfcd799a-631b-4ee3-8a44-8d0077f755c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1   Drugs That May Increase the Risk of Hypoglycemia
</title>
                     <text>
                        <paragraph>The risk of hypoglycemia associated with AFREZZA use may be increased with antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Dose modification and increased frequency of glucose monitoring may be required when AFREZZA is given concomitantly with these drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="5b7e1566-096f-4c9e-a515-5511b84543d6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2   Drugs That May Decrease the Blood Glucose Lowering Effect of AFREZZA
</title>
                     <text>
                        <paragraph>The glucose lowering effect of AFREZZA may be decreased when given concomitantly with atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when AFREZZA is given concomitantly with these drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="875e3e5f-59e1-4687-9c41-5864dcc1fc0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3   Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of AFREZZA
</title>
                     <text>
                        <paragraph>The glucose lowering effect of AFREZZA may be increased or decreased when co-administered with alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose modification and increased frequency of glucose monitoring may be required when AFREZZA is given concomitantly with these drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s35">
                     <id root="a06ee361-1f3c-4b29-a4e7-de0708c75af8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4   Drugs That May Affect Hypoglycemia Signs and Symptoms
</title>
                     <text>
                        <paragraph>The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are given concomitantly with AFREZZA.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="3a77e891-053f-433a-b752-6fb5e5972690"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s37">
                     <id root="85b86a53-7418-49f0-bede-1e94a15cd209"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1   Pregnancy
</title>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s38">
                           <id root="d073b28d-b343-4474-899a-7a1e53b3e00a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited available data with AFREZZA use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. Available information from published studies with human insulin use during pregnancy has not reported a clear association with human insulin and adverse developmental outcomes (<content styleCode="italics">see <linkHtml href="#s41">Data</linkHtml>
                                 </content>). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (<content styleCode="italics">see <linkHtml href="#s39">Clinical Considerations</linkHtml>
                                 </content>). In animal reproduction studies, there were no adverse developmental outcomes with subcutaneous administration of carrier particles (vehicle without insulin) to pregnant rats during organogenesis at doses 21 times the human daily dose of 99 mg AFREZZA, based on AUC <content styleCode="italics">(see <linkHtml href="#s41">Data</linkHtml>)</content>.
</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with HbA1c &gt;7 and has been reported to be as high as 20-25% in women with HbA1c &gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s39">
                           <id root="739222ae-ef5e-4013-b495-184c9e5a4293"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                           <component>
                              <section ID="s40">
                                 <id root="9aca6601-5899-466a-a574-dfc30b4b6462"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                                    </paragraph>
                                    <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia- related morbidity.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s41">
                           <id root="c0cd4032-aafe-4bc4-b3f4-dcfaba4c3fbb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                           <component>
                              <section ID="s42">
                                 <id root="7b20c0aa-648e-4699-8c6d-e31e820e39eb"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>There are limited data with AFREZZA use in pregnant women. Published data do not report a clear association with human insulin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when human insulin is used during pregnancy. However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and lack of blinding.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230227"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s43">
                                 <id root="16ff5bd3-6d6d-413d-81b1-409f79e23ba7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 6 through 17 (organogenesis), no major malformations were observed at doses up to 100 mg/kg/day (21 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).
</paragraph>
                                    <paragraph>In pregnant rabbits given subcutaneous doses of 2, 10, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through 19 (organogenesis), adverse maternal effects were observed in all dose groups (at human systemic exposure following a daily dose of 99 mg AFREZZA, based on AUC).
</paragraph>
                                    <paragraph>In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through lactation day 20 (weaning), decreased epididymis and testes weights were observed in F1 male offspring, however, no decrease in fertility was noted, and impaired learning were observed in F1 pups at ³ 30 mg/kg/day (6 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).
</paragraph>
                                 </text>
                                 <effectiveTime value="20230227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s44">
                     <id root="e7ee5cf5-6002-41cf-bbe9-c15626437bf5"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2   Lactation
</title>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s45">
                           <id root="08011c1e-dfcb-480d-a29b-664582207683"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of AFREZZA in human milk, the effects on the breastfed infant, or the effects on milk production. One small published study reported that exogenous subcutaneous insulin was present in human milk. No adverse effects in infants were noted. The carrier particles are present in rat milk (<content styleCode="italics">see <linkHtml href="#s46">Data</linkHtml>
                                 </content>). Potential adverse reactions that are related to inhalational administration of AFREZZA are unlikely to be associated with potential exposure of AFREZZA through breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AFREZZA and any potential adverse effects on the breastfed infant from AFREZZA or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s46">
                           <id root="27cc5563-4c33-4a67-8aa9-1990c5914d63"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Subcutaneous administration of the carrier particle in lactating rats resulted in excretion of the carrier particle in rat milk at levels that were approximately 10% of the maternal exposure. Given the results of the rat study, it is highly likely that the insulin and carrier in AFREZZA are excreted in human milk.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s47">
                     <id root="ff8eb8dc-b2b4-4f80-8794-c6c909a068a3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4   Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of AFREZZA to improve glycemic control in pediatric patients with diabetes mellitus has not been established. AFREZZA has not been studied in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="5eae5fc8-b8f1-433e-81bf-26484c08d647"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5   Geriatric Use
</title>
                     <text>
                        <paragraph>In the AFREZZA clinical studies<content styleCode="italics">,</content> 671 (12%) patients were 65 years of age or older, of which 42 (0.8%) were 75 years of age or older. In these studies, 381 (13%) of AFREZZA-treated patients were 65 years of age or older, of which 20 (0.7%) were 75 years of age or older. No overall differences in effectiveness of AFREZZA have been observed between patients 65 years of age and older and younger adult patients <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s68">14</linkHtml>)]</content>. Clinical studies of AFREZZA did not include sufficient numbers of patients 65 years of age and older to determine whether there were differences in safety between these patients and younger adult patients.
</paragraph>
                        <paragraph>Pharmacokinetic and pharmacodynamic studies to assess the effect of age on pharmacokinetics or pharmacodynamics on insulin human, respectively, have not been conducted.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="a1438708-6385-4921-8447-72a16dd47542"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6   Hepatic Impairment
</title>
                     <text>
                        <paragraph>The effect of hepatic impairment on the pharmacokinetics of AFREZZA has not been studied. Frequent glucose monitoring and a lower dosage may be necessary in AFREZZA-treated patients with hepatic impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="e7323f5d-54eb-442a-b185-42cd17ae8e0c"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7   Renal Impairment
</title>
                     <text>
                        <paragraph>The effect of renal impairment on the pharmacokinetics of AFREZZA has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. Frequent glucose monitoring and a lower dosage may be necessary in AFREZZA-treated patients with renal impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s51">
               <id root="8d9fac50-67db-49cd-b396-4934aaf963bb"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE
</title>
               <text>
                  <paragraph>Excess insulin administration may cause hypoglycemia and hypokalemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>, <linkHtml href="#s22">5.8</linkHtml>)]</content>.
</paragraph>
                  <paragraph>Mild episodes of hypoglycemia due to insulin overdose can usually be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed.
</paragraph>
                  <paragraph>Severe episodes of hypoglycemia (due to insulin overdose) with coma, seizure, or neurologic impairment may be treated with intramuscular or subcutaneous glucagon or concentrated intravenous glucose. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of hypoglycemia. Hypokalemia should be corrected appropriately.
</paragraph>
               </text>
               <effectiveTime value="20230227"/>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="d88e5794-8347-4289-ab63-5bd8c66365aa"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION
</title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s53">
                     <id root="0d9b3e6a-0912-4d83-be2f-f7b500802272"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.1   AFREZZA Cartridges
</title>
                     <text>
                        <paragraph>Human insulin is a rapid acting human insulin produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of <content styleCode="italics">Escherichia coli</content> (K12). Chemically, human insulin has the empirical formula C<sub>257</sub>H<sub>383</sub>N<sub>65</sub>O<sub>77</sub>S<sub>6</sub> and a molecular weight of 5808. Human insulin has the following primary amino acid sequence:
</paragraph>
                        <renderMultiMedia ID="f03" referencedObject="mm03"/>
                        <paragraph>AFREZZA (human insulin) inhalation powder is available in single-use plastic cartridges filled with a white powder containing insulin (human), which is administered via oral inhalation using the AFREZZA Inhaler only.
</paragraph>
                        <paragraph>Insulin is adsorbed onto carrier particles consisting of fumaryl diketopiperazine (FDKP) and polysorbate 80.
</paragraph>
                        <paragraph>AFREZZA Inhalation Powder is a dry powder supplied as 4 unit, 8 unit or 12 unit cartridges.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <observationMedia ID="mm03">
                           <text>Primary Amino Acid Sequence
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="afr01-0005-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="026689e4-b259-4260-b4f2-08a14bf51416"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.2   AFREZZA Inhaler
</title>
                     <text>
                        <paragraph>The AFREZZA Inhaler is breath-powered by the patient. When the patient inhales through the device, the powder is aerosolized and delivered to the lung. The amount of AFREZZA delivered to the lung will depend on individual patient factors.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s55">
               <id root="7e2ad62a-961d-45c8-aba2-92c5d0f4013e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s56">
                     <id root="ddebea59-e6dc-4a82-bfb6-14ff2a503ff8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1   Mechanism of Action
</title>
                     <text>
                        <paragraph>Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s57">
                     <id root="ff7fe34e-0659-4e97-b974-e4ff0c8ab2f0"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2   Pharmacodynamics
</title>
                     <text>
                        <paragraph>The time course of insulin action (i.e., glucose lowering) may vary considerably in different patients or within the same patient. The average pharmacodynamic profile [i.e., glucose lowering effect measured by glucose infusion rate (GIR) over time in a euglycemic clamp study] after administration of a single AFREZZA dose of 4, 12, and 48 units in 30 patients with type 1 diabetes is shown in <linkHtml href="#fig3">Figure 3(A)</linkHtml>, and key characteristics regarding the timing of the effects are described in <linkHtml href="#t4">Table 4</linkHtml>:
</paragraph>
                        <table ID="t4" width="100%">
                           <caption>Table 4.  Timing of Insulin Effect (i.e., mean pharmacodynamics effect) After Administration of a Single AFREZZA Dose in Patients (N=30) with Type 1 Diabetes Mellitus
</caption>
                           <col width="35.000%" align="left"/>
                           <col width="21.675%" align="left"/>
                           <col width="20.825%" align="left"/>
                           <col width="22.500%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Parameter for Insulin Effect</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">AFREZZA 4 units</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">AFREZZA 12 units</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">AFREZZA 48 units</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Time to first measurable effect
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~12 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~12 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~12 minutes
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Time to peak effect
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~35 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~45 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~55 minutes
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Time for effect to return to baseline
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~90 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~180 minutes
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">~270 minutes
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="fig3">
                           <content styleCode="bold">Figure 3.  Results After Administration of AFREZZA 4, 12, and 48 Units in Patients with T1DM (N=30) A) Mean Insulin Effect (Baseline-Corrected Glucose Infusion Rate); and B) Pharmacokinetic (Baseline-Corrected Serum Insulin Concentration Profiles)</content>
                        </paragraph>
                        <renderMultiMedia ID="f04" referencedObject="mm04"/>
                        <paragraph>On average, the pharmacodynamics effect of AFREZZA, measured as area under the glucose infusion rate – time curve (AUC GIR) increased linearly with doses up to 48 units (106, 387, and 1581 mg/kg for 4, 12, and 48 units doses, respectively).
</paragraph>
                        <paragraph>Intrapatient variability in AUC GIR and GIR<sub>max</sub> was approximately 28% (95% CI 21-42%) and 27% (95% CI 20-40%), respectively.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <observationMedia ID="mm04">
                           <text>Figure 3
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="afr01-0005-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="42677429-8590-4754-9063-a446357af178"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3   Pharmacokinetics
</title>
                     <text>
                        <paragraph>The area under the plasma concentration versus time curve (AUC) of insulin increased dose proportionally up to 48 units. Intrapatient variability of AUC and peak concentration (C<sub>max</sub>) of insulin was approximately 16% (95% CI 12-23%) and 21% (95% CI 16-30%), respectively.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s59">
                           <id root="f2103859-2604-4449-b669-bfcc7f686e8a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic profiles for orally inhaled AFREZZA 4, 12, and 48 units from a study in 30 patients with type 1 diabetes are shown in Figure 5(B). The time to maximum serum insulin concentration (t<sub>max</sub>) ranged from 10-20 minutes after oral inhalation of 4 to 48 units of AFREZZA.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s60">
                           <id root="ee377dcf-602d-4225-83a5-917f4a4f5bb3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The apparent terminal half-life ranged from 120 to 206 minutes. Serum insulin concentrations declined to baseline by approximately 60 to 240 minutes.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                           <component>
                              <section ID="s61">
                                 <id root="2fff5699-3f63-4406-b1ae-941f4de02122"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism and Excretion</content>
                                    </paragraph>
                                    <paragraph>The metabolism and excretion of AFREZZA are comparable to regular human insulin.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s62">
                           <id root="17445782-0e72-489f-a6ee-9bce86c94cd9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carrier Particles</content>
                              </paragraph>
                              <paragraph>Clinical pharmacology studies showed that carrier particles <content styleCode="italics">[see Description (<linkHtml href="#s53">11.1</linkHtml>)]</content> are not metabolized and are eliminated unchanged in the urine following the lung absorption. Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed. The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s63">
                           <id root="bdf1fb5f-5889-4f39-ae0e-afa733564dcd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                           <component>
                              <section ID="s64">
                                 <id root="16bb682d-8e49-4a4e-9b1a-0061a5427bd7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bronchodilators and Inhaled Steroids</content>
                                    </paragraph>
                                    <paragraph>Albuterol increased the AUC insulin after AFREZZA administration by 25% in patients with asthma <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s33">7.2</linkHtml>)].</content> AFREZZA is contraindicated in patients with asthma.
</paragraph>
                                    <paragraph>In a study in healthy volunteers no significant change in insulin exposure was observed when fluticasone was administered following AFREZZA administration.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s65">
                     <id root="5c8f0012-c866-4b9c-950b-1ed1afd2c913"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.6   Immunogenicity
</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of insulin human or of other insulin human products.
</paragraph>
                        <paragraph>Increases in anti-insulin antibody concentrations were observed in patients treated with AFREZZA. Increases in anti-insulin antibodies were observed more frequently in patients treated with AFREZZA than in patients treated with subcutaneously injected mealtime insulin. There was no clinically significant effect of anti-drug antibodies on safety or effectiveness (as measured by HbA1c and fasting plasma glucose) of AFREZZA over the treatment duration of the studies which spanned 3 to 24 months.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s66">
               <id root="497b0a91-9c06-4dc5-b7da-6767a4cb5ac8"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s67">
                     <id root="02714066-e9f6-4ecd-a393-cc76981dfe82"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>In a 104 week carcinogenicity study, rats were given doses up to 46 mg/kg/day of the carrier and up to 1.23 mg/kg/day of insulin, by nose-only inhalation. No increased incidence of tumors was observed at systemic exposures equivalent to the insulin at a daily AFREZZA dose of 99 mg, based on a comparison of relative body surface areas across species.
</paragraph>
                        <paragraph>No increased incidence of tumors was observed in a 26 week carcinogenicity study in transgenic mice (Tg-ras-H2) given doses up to 75 mg/kg/day of carrier and up to 5 mg/kg/day of AFREZZA.
</paragraph>
                        <paragraph>AFREZZA was not genotoxic in Ames bacterial mutagenicity assay and in the chromosome aberration assay, using human peripheral lymphocytes with or without metabolic activation. The carrier alone was not genotoxic in the in vivo mouse micronucleus assay.
</paragraph>
                        <paragraph>In fertility study in male and female rats at subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier (vehicle without insulin), there were no adverse effects on male fertility at doses up to 100 mg/kg/day. In female rats dosed 2 weeks prior to mating until gestation day 7, there was increased pre- and post-implantation loss at 100 mg/kg/day but not at 30 mg/kg/day (21 times and 6 times, respectively the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s68">
               <id root="2bfc1e03-58b0-45c0-9aa2-32c297c1f6e2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES
</title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s69">
                     <id root="1a4a9822-1c0c-47b4-b7da-e1952f081526"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1   Overview of Clinical Studies of AFREZZA in Adults for Diabetes Mellitus
</title>
                     <text>
                        <paragraph>AFREZZA has been studied in adults with type 1 diabetes in combination with basal insulin. The efficacy of AFREZZA, in combination with basal insulin, in type 1 diabetes patients was compared to insulin aspart in combination with basal insulin.
</paragraph>
                        <paragraph>AFREZZA has been studied in adults with type 2 diabetes in combination with oral antidiabetic drugs. The efficacy of AFREZZA in type 2 diabetes patients was compared to placebo inhalation.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s70">
                     <id root="7a83b1a7-4a0f-41d1-a840-5b686bdd16dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2   Adults with Type 1 Diabetes
</title>
                     <text>
                        <paragraph>Patients with inadequately controlled type 1 diabetes participated in a 24-week, open-label, active-controlled study to evaluate the glucose lowering effect of mealtime AFREZZA used in combination with a basal insulin. Following a 4-week basal insulin optimization period, 344 patients were randomized to AFREZZA by oral inhalation (n=174) or insulin aspart given subcutaneously (n=170) at each meal of the day. All patients received basal insulin. Mealtime insulin doses were titrated to glycemic goals for the first 12 weeks and kept stable for the last 12 weeks of the study.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s71">
                           <id root="ba790bf1-2bd1-46af-95fe-bdad9093dfc7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Results</content>
                              </paragraph>
                              <paragraph>At Week 24, treatment with mealtime AFREZZA and basal insulin provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin of 0.4%. AFREZZA and basal insulin provided less HbA1c reduction than insulin aspart and basal insulin, and the difference was statistically significant. More patients in the insulin aspart and basal insulin group achieved the HbA1c target of ≤7% (<linkHtml href="#t5">Table 5</linkHtml>).
</paragraph>
                              <table ID="t5" width="100%">
                                 <caption>Table 5. Results at Week 24 in an Active-Controlled Study of Mealtime AFREZZA plus Basal Insulin in Adults with Type 1 Diabetes
</caption>
                                 <col width="55.467%" align="left"/>
                                 <col width="22.267%" align="left"/>
                                 <col width="22.267%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Adjusted mean was obtained using a Mixed Model Repeated Measures (MMRM) approach with HbA1c or FPG as the dependent variable and treatment, visit, region, basal insulin stratum, and treatment by visit interaction as fixed factors, and corresponding baseline as a covariate. An autoregression (1) [AR(1)] covariance structure was used.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Data at 24 weeks were available from 131 (75%) and 150 (88%) patients randomized to the AFREZZA and insulin aspart groups, respectively.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> The percentage was calculated based on the number of patients randomized to the trial.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">AFREZZA + Basal Insulin (N=174)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Insulin Aspart + Basal Insulin<br/>(N=170)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="left" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Baseline (adjusted mean<sup>a</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.94
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.92
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Change from baseline (adjusted mean<sup>a,b</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.40
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Difference from insulin aspart (adjusted mean<sup>a,b</sup>)<br/>      (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.19<br/>(0.02, 0.36)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Percentage of patients achieving HbA1c ≤ 7%<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">27%
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="center" valign="top" styleCode="Botrule Lrule Rrule">     
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Plasma Glucose (mg/dL)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Baseline (adjusted mean<sup>a</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">153.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">151.6
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Change from baseline (adjusted mean<sup>a, b</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-25.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Difference from insulin aspart (adjusted mean<sup>a, b</sup>)<br/>      (95% CI)
</td>
                                       <td colspan="2" align="center" valign="middle" styleCode="Botrule Rrule">-35.4<br/>(-56.3, -14.6)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s72">
                     <id root="79748268-007f-4ef2-8e69-b5ee87fb505f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3   Adults with Type 2 Diabetes
</title>
                     <text>
                        <paragraph>A total of 479 adult patients with type 2 diabetes inadequately controlled on optimal/maximally tolerated doses of metformin only, or 2 or more oral antidiabetic (OAD) agents participated in a 24-week, double-blind, placebo-controlled study. Following a 6-week run-in period, 353 patients were randomized to AFREZZA by oral inhalation (n=177) or an inhaled placebo powder without insulin (n=176). Insulin doses were titrated for the first 12 weeks and kept stable for the last 12 weeks of the study. OADs doses were kept stable in the study.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s73">
                           <id root="1ea7236b-faf0-4125-83ff-5eec1970e185"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Results</content>
                              </paragraph>
                              <paragraph>At Week 24, treatment with AFREZZA plus OADs provided a mean reduction in HbA1c that was statistically significantly greater compared to the HbA1c reduction observed in the placebo plus OADs group (<linkHtml href="#t6">Table 6</linkHtml>).
</paragraph>
                              <table ID="t6" width="100%">
                                 <caption>Table 6. Results at Week 24 in a Placebo-Controlled Study of AFREZZA in Adults with Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Agents
</caption>
                                 <col width="48.800%" align="left"/>
                                 <col width="25.633%" align="left"/>
                                 <col width="25.567%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Adjusted mean was obtained using a Mixed Model Repeated Measures (MMRM) approach with HbA1c or FPG as the dependent variable and treatment, visit, region, and treatment by visit interaction as fixed factors, and corresponding baseline as a covariate. An autoregression (1) [AR(1)] covariance structure was used.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Data at 24 weeks without rescue therapy were available from 139 (79%) and 129 (73%) patients randomized to the AFREZZA and placebo groups, respectively.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> The percentage was calculated based on the number of patients randomized to the trial.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">AFREZZA + Oral Anti-Diabetic Agents<br/>(N=177)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo + Oral Anti-Diabetic Agents<br/>(N=176)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Baseline (adjusted mean<sup>a</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.25
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.27
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Change from baseline (adjusted mean<sup>a,b</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.82
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.42
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Difference from placebo (adjusted mean<sup>a,b</sup>)<br/>      (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-0.40<br/>(-0.57, -0.23)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Percentage (%) of patients achieving HbA1C ≤7%<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">32%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">15%
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule"> 
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Plasma Glucose (mg/dL)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Baseline (adjusted mean<sup>a</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">175.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">175.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Change from baseline (adjusted mean<sup>a,b</sup>)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-11.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-3.8
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Difference from placebo (adjusted mean<sup>a,b</sup>)<br/>      (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-7.4<br/>(-18.0, 3.2)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s74">
               <id root="27f187ac-3fd1-4bf5-a96b-8433822047f7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>AFREZZA (insulin human) Inhalation Powder is available as 4 unit, 8 unit and 12 unit single-use cartridges. Three cartridges are contained in a single cavity of a blister strip. Each card contains 5 blister strips (each containing three cartridges) separated by perforations for a total of 15 cartridges. Two cards of the same cartridge strength are packaged in a foil laminate overwrap (30 cartridges per foil package).
</paragraph>
                  <paragraph>The cartridges are color-coded, blue for 4 units, green for 8 units and yellow for 12 units. Each cartridge is marked with “afrezza” and “4 units”, “8 units” or “12 units”.
</paragraph>
                  <paragraph>The AFREZZA Inhaler is individually packaged in a clear overwrap. The inhaler is fully assembled with a removable mouthpiece cover. The AFREZZA Inhaler can be used for up to 15 days from the date of first use. After 15 days of use, the inhaler must be discarded and replaced with a new inhaler.
</paragraph>
                  <paragraph>AFREZZA (insulin human) Inhalation Powder is available in the following configurations:
</paragraph>
                  <table width="100%">
                     <col width="15.836%" align="left"/>
                     <col width="17.503%" align="left"/>
                     <col width="20.020%" align="left"/>
                     <col width="15.836%" align="left"/>
                     <col width="12.669%" align="left"/>
                     <col width="18.136%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">NDC</content>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Cartridge Strength</content>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Quantity of Cartridges per Strength</content>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Total Quantity of Cartridges per Kit</content>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Total Units in Kit</content>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Number of Inhalers</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-874-90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">4 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">360 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-878-90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">8 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">720 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-891-90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">12 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">1080 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-898-18
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">8 units, 12 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">180
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">1800 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-880-18<br/>(Titration Pack)
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">4 units, 8 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">90
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">180
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">1080 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">47918-902-18<br/>(Titration Pack)
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">4 units, 8 units, 12 units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">60
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">180
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">1440 Units
</td>
                           <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s75">
                     <id root="82b91988-994d-4712-a923-53f9330e5c19"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage</content>:
</paragraph>
                        <paragraph>Not in Use: Refrigerated Storage 2-8ºC (36-46ºF)
</paragraph>
                        <table width="100%">
                           <col width="50.000%" align="left"/>
                           <col width="50.000%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">* If a foil package, blister card or strip is not refrigerated, the contents must be used within 10 days.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Sealed (Unopened) Foil Package
</td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">May be stored until the Expiration Date*
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sealed (Unopened) Blister Cards + Strips
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Must be used within 1 month*
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In Use: Room Temperature Storage 25ºC (77ºF), excursions permitted 15-30ºC (59-86ºF)
</paragraph>
                        <table width="100%">
                           <col width="50.000%" align="left"/>
                           <col width="50.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Sealed (Unopened) Blister Cards + Strips
</td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">Must be used within 10 days
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Opened Strips
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Must be used within 3 days
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Do not put a blister card or strip back into the refrigerator after being stored at room temperature.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                     <component>
                        <section ID="s76">
                           <id root="08e2f48d-2839-4a59-aea9-5d87b13a68f1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Inhaler Storage</content>:
</paragraph>
                              <paragraph>Store refrigerated or at room temperature 2-25ºC (36-77ºF); excursions permitted. Inhaler may be stored refrigerated, but should be at room temperature before use.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s77">
                           <id root="e6b6151a-4418-4e83-bc16-8614d0110258"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Handling</content>:
</paragraph>
                              <paragraph>Before use, cartridges should be at room temperature for 10 minutes.
</paragraph>
                           </text>
                           <effectiveTime value="20230227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s78">
               <id root="ad72fd90-03d0-4889-a70e-e02878d7cdbf"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#s87">Medication Guide</linkHtml> and <linkHtml href="#s88">Instructions for Use</linkHtml>).
</paragraph>
                  <paragraph>Instruct patients to use AFREZZA only with the AFREZZA inhaler.
</paragraph>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="s79">
                     <id root="7c1edc8c-9515-4e46-b6de-6ac333888305"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that the most common adverse reactions associated with the use of AFREZZA are hypoglycemia, cough, and throat pain or irritation.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s80">
                     <id root="58b55b44-e90c-49f0-988e-397ce237f904"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise women with diabetes to inform their physician if they are pregnant or are planning to become pregnant while using AFREZZA.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s81">
                     <id root="75922958-948d-4177-a19f-31713c0c1cba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Bronchospasm in Patients with Chronic Lung Disease</content>
                        </paragraph>
                        <paragraph>Advise patients that if they experience any respiratory difficulty after inhalation of AFREZZA, they should report it to their healthcare provider immediately for assessment.
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s82">
                     <id root="cc7edc99-ab1b-4798-b8e0-65252880fd3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypoglycemia</content>
                        </paragraph>
                        <paragraph>Instruct patients on self-management procedures including glucose monitoring, proper inhalation technique, and management of hypoglycemia and hyperglycemia especially at initiation of AFREZZA therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, or skipped meals.
</paragraph>
                        <paragraph>Instruct patients on the management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s83">
                     <id root="1bdb37ec-51b4-40e4-9d47-2738c4a95051"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Decline in Pulmonary Function</content>
                        </paragraph>
                        <paragraph>Inform patients that AFREZZA can cause a decline in lung function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s84">
                     <id root="8ee7250b-927b-417c-8978-ee31357e7f95"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lung Cancer</content>
                        </paragraph>
                        <paragraph>Inform patients to promptly report any signs or symptoms potentially related to lung cancer <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s85">
                     <id root="08d6cf0e-bdbe-405a-bf35-345045c0591a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diabetic Ketoacidosis</content>
                        </paragraph>
                        <paragraph>Instruct patients to carefully monitor their blood glucose during illness, infection, and other risk situations for diabetic ketoacidosis and to contact their healthcare provider if their blood glucose control worsens <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="s86">
                     <id root="4a3c3308-fda0-44c4-8ddc-7d0cc8554f7e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that hypersensitivity reactions can occur with insulin therapy including AFREZZA. Inform patients on the symptoms of hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Manufactured by: MannKind Corporation, Danbury, CT 06810<br/>US License No. #2190<br/>© 2016 – 2023 MannKind Corporation
</paragraph>
                        <paragraph>AFREZZA is a registered trademark of MannKind Corporation<br/>Patent: www.mannkindcorp.com/patent-notices
</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s87">
               <id root="e5e5099c-3786-4e90-b031-a3cdd81cfdc5"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="80.250%" align="left"/>
                     <col width="19.750%" align="left"/>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top">
                              <paragraph styleCode="footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration
</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph styleCode="footnote">Revised 02/2023
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>
                              <content styleCode="bold">AFREZZA® (uh-FREZZ-uh)</content>
                              <br/>
                              <content styleCode="bold">(insulin human)</content>
                              <br/>
                              <content styleCode="bold">inhalation powder, for oral inhalation use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph ID="p01">
                                 <content styleCode="bold">What is the most important information I should know about AFREZZA?</content>
                                 <br/>
                                 <content styleCode="bold">AFREZZA can cause serious side effects, including:</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Sudden lung problems (bronchospasms). Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD).</content> Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is AFREZZA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>AFREZZA is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults with diabetes mellitus.
</item>
                                 <item>AFREZZA is not for use to treat diabetic ketoacidosis. AFREZZA must be used with basal insulin in people who have type 1 diabetes mellitus.
</item>
                                 <item>It is not known if AFREZZA is safe and effective for use in people who smoke. AFREZZA is not for use in people who smoke or have recently stopped smoking (less than 6 months).
</item>
                                 <item>It is not known if AFREZZA is safe and effective in children under 18 years of age.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Who should not use AFREZZA?</content>
                              <br/>
                              <content styleCode="bold">Do not use AFREZZA if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Have chronic lung problems such as asthma or COPD.
</item>
                                 <item>Are allergic to regular human insulin or any of the ingredients in AFREZZA. See the end of this Medication Guide for a complete list of ingredients in AFREZZA.
</item>
                                 <item>
                                    <content styleCode="bold">Are having an episode of low blood sugar (hypoglycemia).</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I tell my healthcare provider before using AFREZZA?</content>
                              <br/>
                              <content styleCode="bold">Before using AFREZZA, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Have lung problems such as asthma or COPD
</item>
                                 <item>Have or have had lung cancer
</item>
                                 <item>Are using any inhaled medications
</item>
                                 <item>Smoke or have recently stopped smoking
</item>
                                 <item>Have kidney or liver problems
</item>
                                 <item>Are pregnant, planning to become pregnant, or are breastfeeding. AFREZZA may harm your unborn or breastfeeding baby.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.<br/>
                              <content styleCode="bold">Before you start using AFREZZA, talk to your healthcare provider about low blood sugar and how to manage it.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I use AFREZZA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the detailed <content styleCode="bold">
                                       <linkHtml href="#s88">Instructions for Use</linkHtml>
                                    </content> that comes with your AFREZZA.
</item>
                                 <item>Take AFREZZA exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much AFREZZA to use and when to use it.
</item>
                                 <item>Know the strength of AFREZZA you use. <content styleCode="bold">Do not</content> change the amount of AFREZZA you use unless your healthcare provider tells you to.
</item>
                                 <item>Take AFREZZA at the beginning of your meal.
</item>
                                 <item>
                                    <content styleCode="bold">Check your blood sugar levels.</content> Ask your healthcare provider what your blood sugar should be and when you should check your blood sugar levels.
</item>
                                 <item>
                                    <content styleCode="bold">Keep AFREZZA and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Your dose of AFREZZA may need to change because of:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What should I avoid while using AFREZZA?</content>
                              <br/>
                              <content styleCode="bold">While using AFREZZA do not:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Drive or operate heavy machinery, until you know how AFREZZA affects you
</item>
                                 <item>Drink alcohol or use over-the-counter medicines that contain alcohol
</item>
                                 <item>Smoke
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of AFREZZA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">AFREZZA may cause serious side effects that can lead to death, including:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">See “<linkHtml href="#p01">What is the most important information I should know about AFREZZA?</linkHtml>”</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Low blood sugar (hypoglycemia).</content> Signs and symptoms that may indicate low blood sugar include:<list listType="unordered" styleCode="Circle">
                                       <item>Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Decreased lung function.</content> Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it and yearly after that.
</item>
                                 <item>
                                    <content styleCode="bold">Lung cancer.</content> In studies of AFREZZA in people with diabetes, lung cancer occurred in a few more people who were taking AFREZZA than in people who were taking other diabetes medications. There were too few cases to know if lung cancer was related to AFREZZA. If you have lung cancer, you and your healthcare provider should decide if you should use AFREZZA.
</item>
                                 <item>
                                    <content styleCode="bold">Diabetic ketoacidosis.</content> Talk to your healthcare provider if you have an illness. Your AFREZZA dose or how often you check your blood sugar may need to be changed.
</item>
                                 <item>
                                    <content styleCode="bold">Severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>A rash over your whole body, trouble breathing, a fast heartbeat, or sweating.
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Low potassium in your blood (hypokalemia).</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Heart failure.</content> Taking certain diabetes pills called thiazolidinediones or “TZDs” with AFREZZA may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with AFREZZA. Your healthcare provider should monitor you closely while you are taking TZDs with AFREZZA. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:<list listType="unordered" styleCode="Circle">
                                       <item>Shortness of breath, swelling of your ankles or feet, sudden weight gain.
</item>
                                    </list>
                                    <paragraph>Treatment with TZDs and AFREZZA may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.
</paragraph>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Get emergency medical help if you have:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of AFREZZA include:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Low blood sugar (hypoglycemia), cough, sore throat.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">These are not all the possible side effects of AFREZZA.</content> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of AFREZZA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use AFREZZA for a condition for which it was not prescribed. Do not give AFREZZA to other people, even if they have the same symptoms that you have. It may harm them.<br/>This Medication Guide summarizes the most important information about AFREZZA. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about AFREZZA that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in AFREZZA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> human insulin<br/>
                              <content styleCode="bold">Inactive ingredients:</content> fumaryl diketopiperazine, polysorbate 80
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">AFREZZA is a registered trademark of MannKind Corporation<br/>Patent: www.mannkindcorp.com/patent-notices<br/>Manufactured by: MannKind Corporation, Danbury, CT 06810<br/>US License No. #2190<br/>© 2016 – 2023 MannKind Corporation<br/>For more information, go to www.AFREZZA.com or call MannKind Corporation at 1-877-323-8505.
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230227"/>
            </section>
         </component>
         <component>
            <section ID="s88">
               <id root="2111f964-dc49-4bf6-992d-70bd21adcb67"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE<br/>AFREZZA® (uh-FREZZ-uh)<br/>(insulin human) <br/>inhalation powder, for oral inhalation use</content>
                  </paragraph>
                  <paragraph>This “Instructions for Use” contains information on how to use AFREZZA<sup>®</sup> (insulin human) Inhalation Powder.
</paragraph>
                  <paragraph>Read this Instructions for Use before you start using AFREZZA and each time you get a new AFREZZA Inhaler. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Your healthcare provider should show you how to use your AFREZZA Inhaler the right way before you use it for the first time.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information about AFREZZA:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">AFREZZA comes in 3 strengths</content> (see <linkHtml href="#f05">Figure A</linkHtml>):<list listType="unordered" styleCode="Circle">
                           <item>4 units (blue cartridge)
</item>
                           <item>8 units (green cartridge)
</item>
                           <item>12 units (yellow cartridge)
</item>
                        </list>
                     </item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f05" referencedObject="mm05"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">Figure A</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>If your prescribed AFREZZA dose is higher than 12 units, you will need to use more than 1 cartridge.
</item>
                     <item>If you need to use more than 1 cartridge for your dose, throw away the used cartridge before getting a new one. You can tell when a cartridge has been used, because the cup has moved to the center.
</item>
                     <item>
                        <content styleCode="bold">Do not try to open the AFREZZA cartridges.</content> The AFREZZA Inhaler opens the cartridge automatically during use.
</item>
                     <item>
                        <content styleCode="bold">AFREZZA cartridges should only be used with the AFREZZA Inhaler. Do not</content> try to breathe in the AFREZZA insulin powder in any other way. <content styleCode="bold">Do not</content> put cartridges in your mouth and <content styleCode="bold">do not</content> swallow cartridges.
</item>
                     <item>Use only 1 AFREZZA Inhaler at a time. The same inhaler should be used for the 4 unit, 8 unit or 12 unit cartridges.
</item>
                     <item>Store the inhaler in a clean, dry place with the mouthpiece cover on until your next dose.
</item>
                     <item>Throw away your AFREZZA Inhaler after 15 days and get a new one.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you are having problems with your AFREZZA Inhaler or if it breaks and you need a new one, call 1-877-323-8505.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Know your AFREZZA Inhaler:</content>
                  </paragraph>
                  <renderMultiMedia ID="f06" referencedObject="mm06"/>
                  <paragraph>
                     <content styleCode="bold">Know your AFREZZA cartridges:</content>
                  </paragraph>
                  <renderMultiMedia ID="f07" referencedObject="mm07"/>
                  <table width="100%">
                     <col width="35.000%" align="left"/>
                     <col width="65.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">How to take your dose of AFREZZA:</content>
                              <br/>Always be sure you have the right number of AFREZZA cartridges for your dose available before you start. AFREZZA cartridges must only be used with the AFREZZA Inhaler.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule">
                              <content styleCode="bold">Step 1: Select the AFREZZA cartridges for your dose</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule">
                              <renderMultiMedia ID="f08" referencedObject="mm08"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">If your prescribed AFREZZA dose is more than 12 units</content> you will need to use <content styleCode="bold">more than 1 cartridge</content> to get your right dose.<br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule">Use the dosage chart below to determine the least number<br/>of AFREZZA cartridges you can use for your dose. Other<br/>cartridge combinations can be used.<br/>
                              <br/>
                              <renderMultiMedia ID="f09" referencedObject="mm09"/>
                              <content styleCode="bold">Figure B</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule">
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f10" referencedObject="mm10"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle" styleCode="Botrule">
                              <content styleCode="bold">Select Cartridges</content>
                              <br/>
                              <content styleCode="bold">Important: Use the AFREZZA dose chart above (see <linkHtml href="#f09">Figure B</linkHtml>)</content> to help you choose the right number of AFREZZA cartridges needed for your dose.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule">
                              <renderMultiMedia ID="f11" referencedObject="mm11"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule">
                              <content styleCode="bold">Open Packages</content>
                              <br/>
                              <br/>Remove a blister card from the foil package.<br/>Tear along perforation to remove one strip.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule">
                              <renderMultiMedia ID="f12" referencedObject="mm12"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule">
                              <content styleCode="bold">Push Cartridges to Remove</content>
                              <br/>Remove a cartridge from the strip by pressing on the clear side to push the cartridge out. Remove the right number of cartridges for your dose. Pushing on the cup will not damage the cartridge.<br/>
                              <content styleCode="bold">AFREZZA cartridges left over in an opened strip must be used within 3 days.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule">
                              <renderMultiMedia ID="f13" referencedObject="mm13"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule">
                              <content styleCode="bold">Before Proceeding:</content>
                              <br/>Check that you have the right AFREZZA cartridge(s) for your dose.<br/>Use only 1 inhaler for multiple cartridges. Throw away your AFREZZA Inhaler after 15 days and get a new one.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="35.000%" align="left"/>
                     <col width="65.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 2: Loading a cartridge</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule">
                              <paragraph>
                                 <renderMultiMedia ID="f14" referencedObject="mm14"/>
                              </paragraph>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Hold Inhaler</content>
                              <br/>
                              <br/>Hold the inhaler level in one (1) hand with the white mouthpiece on the top and purple base on the bottom.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule">
                              <paragraph>
                                 <renderMultiMedia ID="f15" referencedObject="mm15"/>
                              </paragraph>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Open Inhaler</content>
                              <br/>
                              <br/>Open the inhaler by lifting the white mouthpiece to a vertical position.<br/>Before you put the AFREZZA cartridge in your inhaler, make sure it has been at <content styleCode="bold">room temperature for 10 minutes</content>.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule">
                              <paragraph>
                                 <renderMultiMedia ID="f16" referencedObject="mm16"/>
                              </paragraph>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Place Cartridge</content>
                              <br/>
                              <br/>Hold the cartridge with the cup facing down.<br/>
                              <br/>Line up the cartridge with the opening in the inhaler. The pointed end of the cartridge should line up with the pointed end in the inhaler.<br/>Place the cartridge into the inhaler. Be sure that the cartridge lies flat in the inhaler.<br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f17" referencedObject="mm17"/>
                              <content styleCode="bold">If any of these occur, throw away the cartridge</content>
                              <br/>
                              <content styleCode="bold">and load a new cartridge.</content>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f18" referencedObject="mm18"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Close Inhaler</content>
                              <br/>
                              <br/>Lower the mouthpiece to close the inhaler (this will open the drug cartridge).<br/>You should feel a snap when the inhaler is closed.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 3: Inhaling AFREZZA</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f19" referencedObject="mm19"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Remove the Mouthpiece Cover</content>
                              <br/>
                              <br/>
                              <content styleCode="bold">Important:</content> Keep the inhaler level during and after removal of the purple mouthpiece cover.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f20" referencedObject="mm20"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <br/>
                              <renderMultiMedia ID="f21" referencedObject="mm21"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Exhale</content>
                              <br/>
                              <br/>Hold the inhaler away from your mouth and fully blow out (exhale).
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f22" referencedObject="mm22"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Position Inhaler in Mouth</content>
                              <br/>
                              <br/>Keeping your head level, place the mouthpiece in your mouth and <content styleCode="bold">tilt the inhaler down towards your chin, as shown.</content>
                              <br/>
                              <br/>Close your lips around the mouthpiece to form a seal.<br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">Tilt the inhaler downward while keeping your head level.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f23" referencedObject="mm23"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Inhale Deeply and Hold Breath</content>
                              <br/>
                              <br/>With your mouth closed around the mouthpiece, <content styleCode="bold">inhale deeply through the inhaler</content>.<br/>
                              <content styleCode="bold">Hold your breath</content> for as long as comfortable and at the same time remove the inhaler from your mouth. After holding your breath, exhale and continue to breathe normally.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="35.000%" align="left"/>
                     <col width="65.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 4: Removing a used cartridge</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f24" referencedObject="mm24"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Replace Mouthpiece Cover</content>
                              <br/>
                              <br/>Place the purple mouthpiece cover back onto the inhaler.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f25" referencedObject="mm25"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Open Inhaler</content>
                              <br/>
                              <br/>Open the inhaler by lifting up the white mouthpiece.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f26" referencedObject="mm26"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Remove Cartridge</content>
                              <br/>Remove the cartridge from the purple base.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule">
                              <renderMultiMedia ID="f27" referencedObject="mm27"/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Throw away (or recycle) the Cartridge</content>
                              <br/>
                              <br/>Throw away the used cartridge in your regular household trash.<br/>Alternatively, the used cartridge (composed of HDPE, assigned recycling number 2) can be recycled.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="41.900%" align="left"/>
                     <col width="58.100%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Multiple cartridge dosing</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule">
                              <content styleCode="bold">If you need more than one (1) AFREZZA cartridge for your dose, see the AFREZZA dosage chart above (<linkHtml href="#f09">Figure B</linkHtml>).</content>
                              <br/>
                              <br/>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f28" referencedObject="mm28"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <content styleCode="bold">Repeat steps 2 through 4 for each AFREZZA cartridge you need for your prescribed AFREZZA dose.</content>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f29" referencedObject="mm29"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">How should I store AFREZZA?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f30" referencedObject="mm30"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f31" referencedObject="mm31"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f32" referencedObject="mm32"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Caring for your AFREZZA Inhaler:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f33" referencedObject="mm33"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f34" referencedObject="mm34"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f35" referencedObject="mm35"/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%">
                     <col width="5.000%" align="left"/>
                     <col width="45.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="4" align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Switching between AFREZZA and injected insulin:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule">
                              <paragraph>
                                 <renderMultiMedia ID="f36" referencedObject="mm36"/>
                              </paragraph>
                           </td>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Contact your healthcare provider before switching insulins.</content>
                              <br/>
                              <content styleCode="bold">AFREZZA is a mealtime insulin.</content>
                              <br/>
                              <content styleCode="bold">Do not switch from AFREZZA to a long acting insulin.</content>
                              <br/>
                              <content styleCode="bold">Do not switch from a long acting insulin to AFREZZA.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f37" referencedObject="mm37"/>
                              </paragraph>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <renderMultiMedia ID="f38" referencedObject="mm38"/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Manufactured by: MannKind Corporation<br/>Danbury, CT 06810
</paragraph>
                  <paragraph>US License No. #2190
</paragraph>
                  <paragraph>© 2016 – 2023 MannKind Corporation
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.
</paragraph>
                  <paragraph>Revised: 02/2023
</paragraph>
                  <paragraph>AFREZZA is a registered trademark of MannKind Corporation
</paragraph>
                  <paragraph>Patent: www.mannkindcorp.com/patent-notices
</paragraph>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm05">
                     <text>Figure A
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm06">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm08">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm09">
                     <text>Figure B
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm10">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm11">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm12">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm13">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm14">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm15">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm16">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm17">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm18">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm19">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm20">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm21">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm22">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm23">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm24">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm25">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm26">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm27">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm28">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm29">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm30">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm31">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm32">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm33">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm34">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm35">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm36">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-36.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm37">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-37.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm38">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-38.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s89">
               <id root="657c1147-36cb-43f9-8c3b-56cdc6810a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 90 − 4 unit cartridges and 2 inhalers</content>
                  </paragraph>
                  <paragraph>NDC 47918-874-90
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 4 unit cartridges + 2 inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f39" referencedObject="mm39"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm39">
                     <text>Principal Display Panel 90 − 4 unit cartridges and 2 inhalers
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-39.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s90">
               <id root="83414954-505a-41e8-997a-56579e6a6e87"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 90 – 8 unit cartridges and 2 inhalers</content>
                  </paragraph>
                  <paragraph>NDC 47918-878-90
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 8 unit cartridges + 2 inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f40" referencedObject="mm40"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm40">
                     <text>Principal Display Panel 90 – 8 unit cartridges and 2 inhalers
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-40.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s91">
               <id root="c5aca946-2a31-4209-ae15-38feca57e4fc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 90 – 12 unit cartridges and 2 inhalers</content>
                  </paragraph>
                  <paragraph>NDC 47918-891-90
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 12 unit cartridges + 2 inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f41" referencedObject="mm41"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm41">
                     <text>Principal Display Panel 90 – 12 unit cartridges and 2 inhalers
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-41.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s92">
               <id root="91517c5e-f46d-4b40-b030-02bf712c97da"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 180 cartridges; 60 – 4 unit cartridges, 60 – 8 unit cartridges and 60 – 12 unit cartridges and 2 inhalers (Titration Pack)</content>
                  </paragraph>
                  <paragraph>NDC 47918-902-18
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">60 – 4 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 – 8 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 – 12 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 - inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed<br/>Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f42" referencedObject="mm42"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm42">
                     <text>Principal Display Panel 180 cartridges; 60 – 4 unit cartridges, 60 – 8 unit cartridges and 60 – 12 unit cartridges and 2 inhalers (Titration Pack)
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-42.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s93">
               <id root="c448264f-89e7-4f06-a9bb-de4797aaeac6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 180 cartridges; 90 – 4 unit cartridges and 90 – 8 unit cartridges and 2 inhalers (Titration Pack)</content>
                  </paragraph>
                  <paragraph>NDC 47918-880-18
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">titration pack</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 4 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 8 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 - inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed<br/>Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f43" referencedObject="mm43"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm43">
                     <text>Principal Display Panel 180 cartridges; 90 – 4 unit cartridges and 90 – 8 unit cartridges and 2 inhalers (Titration Pack)
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-43.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s94">
               <id root="051099c7-596d-4a6b-971b-20170972e140"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel 180 cartridges; 90 – 8 unit cartridges and 90 – 12 unit cartridges and 2 inhalers</content>
                  </paragraph>
                  <paragraph>NDC 47918-898-18
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 8 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 – 12 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 - inhalers</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed<br/>Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind®</content>
                  </paragraph>
                  <renderMultiMedia ID="f44" referencedObject="mm44"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm44">
                     <text>Principal Display Panel 180 cartridges; 90 – 8 unit cartridges and 90 – 12 unit cartridges and 2 inhalers
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-44.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s95">
               <id root="8d11bdb0-a0e2-4647-9930-83eea3f595c5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel 27 cartridges; 9 – 4 unit cartridges, 9 – 8 unit cartridges and 9 – 12 unit cartridges and 1 inhaler (Sample Kit)
</title>
               <text>
                  <paragraph>NDC 47918-903-27
</paragraph>
                  <paragraph>Rx ONLY
</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">afrezza</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(insulin human)<br/>Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12 units per<br/>cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">27 single-use cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>Carton Contains:
</paragraph>
                  <paragraph>
                     <content styleCode="bold">9 – 4 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">9 – 8 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">9 – 12 unit cartridges</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 - inhaler</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed<br/>Medication Guide<br/>to each patient
</paragraph>
                  <paragraph>
                     <content styleCode="bold">mannkind</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                  </paragraph>
                  <renderMultiMedia ID="f45" referencedObject="mm45"/>
               </text>
               <effectiveTime value="20230227"/>
               <component>
                  <observationMedia ID="mm45">
                     <text>Principal Display Panel 27 cartridges; 9 – 4 unit cartridges, 9 – 8 unit cartridges and 9 – 12 unit cartridges and 1 inhaler (Sample Kit)
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="afr01-0005-45.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>